389 related articles for article (PubMed ID: 21752907)
1. The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase.
Goldner T; Hewlett G; Ettischer N; Ruebsamen-Schaeff H; Zimmermann H; Lischka P
J Virol; 2011 Oct; 85(20):10884-93. PubMed ID: 21752907
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246.
Lischka P; Hewlett G; Wunberg T; Baumeister J; Paulsen D; Goldner T; Ruebsamen-Schaeff H; Zimmermann H
Antimicrob Agents Chemother; 2010 Mar; 54(3):1290-7. PubMed ID: 20047911
[TBL] [Abstract][Full Text] [Related]
3. In vitro drug combination studies of Letermovir (AIC246, MK-8228) with approved anti-human cytomegalovirus (HCMV) and anti-HIV compounds in inhibition of HCMV and HIV replication.
Wildum S; Zimmermann H; Lischka P
Antimicrob Agents Chemother; 2015; 59(6):3140-8. PubMed ID: 25779572
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic characterization of two naturally occurring human Cytomegalovirus sequence polymorphisms located in a distinct region of ORF UL56 known to be involved in in vitro resistance to letermovir.
Goldner T; Zimmermann H; Lischka P
Antiviral Res; 2015 Apr; 116():48-50. PubMed ID: 25637709
[TBL] [Abstract][Full Text] [Related]
5. Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance.
Piret J; Boivin G
Antiviral Res; 2019 Mar; 163():91-105. PubMed ID: 30690043
[TBL] [Abstract][Full Text] [Related]
6. Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure.
Goldner T; Hempel C; Ruebsamen-Schaeff H; Zimmermann H; Lischka P
Antimicrob Agents Chemother; 2014; 58(1):610-3. PubMed ID: 24189264
[TBL] [Abstract][Full Text] [Related]
7. Mutual Interplay between the Human Cytomegalovirus Terminase Subunits pUL51, pUL56, and pUL89 Promotes Terminase Complex Formation.
Neuber S; Wagner K; Goldner T; Lischka P; Steinbrueck L; Messerle M; Borst EM
J Virol; 2017 Jun; 91(12):. PubMed ID: 28356534
[TBL] [Abstract][Full Text] [Related]
8. The human cytomegalovirus UL51 protein is essential for viral genome cleavage-packaging and interacts with the terminase subunits pUL56 and pUL89.
Borst EM; Kleine-Albers J; Gabaev I; Babic M; Wagner K; Binz A; Degenhardt I; Kalesse M; Jonjic S; Bauerfeind R; Messerle M
J Virol; 2013 Feb; 87(3):1720-32. PubMed ID: 23175377
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds.
Chou S
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28827420
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Human Cytomegalovirus pUL89 Terminase Subunit Blocks Virus Replication and Genome Cleavage.
Wang Y; Mao L; Kankanala J; Wang Z; Geraghty RJ
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881652
[TBL] [Abstract][Full Text] [Related]
11. A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance.
Chou S
Antiviral Res; 2017 Dec; 148():1-4. PubMed ID: 29107686
[TBL] [Abstract][Full Text] [Related]
12. Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism.
Pilorgé L; Burrel S; Aït-Arkoub Z; Agut H; Boutolleau D
Antiviral Res; 2014 Nov; 111():8-12. PubMed ID: 25194992
[TBL] [Abstract][Full Text] [Related]
13. Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228).
Lischka P; Michel D; Zimmermann H
J Infect Dis; 2016 Jan; 213(1):23-30. PubMed ID: 26113373
[TBL] [Abstract][Full Text] [Related]
14. New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by
Chou S; Satterwhite LE; Ercolani RJ
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914965
[TBL] [Abstract][Full Text] [Related]
15. The human cytomegalovirus terminase complex as an antiviral target: a close-up view.
Ligat G; Cazal R; Hantz S; Alain S
FEMS Microbiol Rev; 2018 Mar; 42(2):137-145. PubMed ID: 29361041
[TBL] [Abstract][Full Text] [Related]
16. In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products.
Komatsu TE; Hodowanec AC; Colberg-Poley AM; Pikis A; Singer ME; O'Rear JJ; Donaldson EF
Antiviral Res; 2019 Sep; 169():104549. PubMed ID: 31279814
[TBL] [Abstract][Full Text] [Related]
17. Targeting the terminase: An important step forward in the treatment and prophylaxis of human cytomegalovirus infections.
Gentry BG; Bogner E; Drach JC
Antiviral Res; 2019 Jan; 161():116-124. PubMed ID: 30472161
[TBL] [Abstract][Full Text] [Related]
18. In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses.
Marschall M; Stamminger T; Urban A; Wildum S; Ruebsamen-Schaeff H; Zimmermann H; Lischka P
Antimicrob Agents Chemother; 2012 Feb; 56(2):1135-7. PubMed ID: 22106211
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacological and clinical effects of letermovir (Prevymis
Ogawa M; Eto T
Nihon Yakurigaku Zasshi; 2019; 153(4):192-198. PubMed ID: 30971660
[TBL] [Abstract][Full Text] [Related]
20. [The terminase complex, a relevant target for the treatment of HCMV infection].
Ligat G; Muller C; Alain S; Hantz S
Med Sci (Paris); 2020 Apr; 36(4):367-375. PubMed ID: 32356713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
